Cart
sales@molnova.com
Avotaciclib
CAS No. 1983983-41-0
Avotaciclib( —— )
Catalog No. M35116 CAS No. 1983983-41-0
Avotaciclib (BEY1107) is a potent, orally active cyclin-dependent kinase 1 (CDK1) inhibitor, suitable for research in locally advanced or metastatic pancreatic cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 181 | Get Quote |
|
| 5MG | 273 | Get Quote |
|
| 10MG | 433 | Get Quote |
|
| 25MG | 689 | Get Quote |
|
| 50MG | 975 | Get Quote |
|
| 100MG | 1278 | Get Quote |
|
| 500MG | 2565 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAvotaciclib
-
NoteResearch use only, not for human use.
-
Brief DescriptionAvotaciclib (BEY1107) is a potent, orally active cyclin-dependent kinase 1 (CDK1) inhibitor, suitable for research in locally advanced or metastatic pancreatic cancer.
-
DescriptionAvotaciclib (BEY1107) is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib can be used for the research of locally advanced or metastatic pancreatic cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1983983-41-0
-
Formula Weight281.27
-
Molecular FormulaC13H11N7O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC1=C(N=C(C=C1)C2=NC(N)=NC=C2)C3=NC(N)=NC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Seufferlein T, et, al. Phase I Trials in Pancreatic Cancer. Translational Pancreatic Cancer Research pp 219-232.
molnova catalog
related products
-
CDK-IN-10
CDK-IN-10 is a cell cycle protein-dependent kinase (CDK) inhibitor with potential anticancer activity for cancer research.
-
Atuveciclib
Atuveciclib (BAY-1143572) is a potent, highly selective, orally bioavailable CDK9/P-TEFb inhibitor with IC50 of 6 nM for CDK9/CyclinT1.
-
LSN2839567
LSN2839567 (Abemaciclib metabolite M2) is the active metabolite of Abemaciclib, a potent CDK4 and CDK6 inhibitor (IC50s: 1-3 nM) with anticancer activity.
